



ANNOUNCEMENT NO. 200

December 14th, 2020

Revenue and EBITDA guidance raised

Despite the COVID-19 situation and a declining USD exchange rate, ChemoMetec has continued its positive development in the second quarter of the financial year 2020/21, where sales developed better than expected especially in the European market.

As a result of the higher revenue and the continued lower than expected sales-related expenses due to the COVID-19 restrictions, ChemoMetec is raising its guidance for both revenue and EBITDA for the 2020/21 financial year.

ChemoMetec now expects revenue in the DKK 250-260 million range, up from DKK 240-250 million, and EBITDA in the DKK 110-115 million range, up from DKK 100-105 million.

Due to the COVID-19 situation, the outlook is subject to greater uncertainty than usual in part because the current restrictions are affecting the company's ability to visit customers.

ChemoMetec expects to release its H1 2020/21 interim report (for the six months to 31 December 2020) on Friday, 5 February 2020.

For further information, please contact

Steen Søndergaard, CEO, ChemoMetec A/S

Tel.: (+45) 4813 1020

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets analytical instruments for cell counting and a wide range of other measurements. ChemoMetec's analytical instruments are marketed to the pharmaceutical industry, biotech and agriculture worldwide. ChemoMetec's customers comprise some of the world's leading pharmaceutical companies, including Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to www.chemometec.com.